Obesity is a complex disease caused by a combination of genetic, behavioral, environmental and social factors. Its effective management requires an integrated approach combining lifestyle changes, psychological support, medical and surgical interventions, as well as political measures aimed at reducing the obesitogenic environment. Among the individual pillars of obesity treatment, incretin therapies have made a significant contribution. Despite their benefits, patient response to treatment with these drugs varies, and their use is often limited by gastrointestinal side effects that reduce long-term patient adherence to treatment. The article discusses selective agonism of the amylin receptor as a potential solution with greater promise than traditional incretin therapies.